| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 124 |
| 1 | METHOTREXATE | 91 |
| 2 | DOXORUBICIN | 26 |
| 3 | CYTARABINE | 22 |
| 4 | CYCLOPHOSPHAMIDE | 20 |
| 5 | CYCLOPHOSPHAMIDE FOR INJECTION | 20 |
| 6 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 20 |
| 7 | CISPLATIN | 17 |
| 8 | PEGASPARGASE | 17 |
| 9 | DEXAMETHASONE | 15 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | GLUCARPIDASE | 2 | 0.0055 |
| 1 | PALIFERMIN | 1 | 0.0026 |
| 2 | GLUTATHIONE | 4 | 0.0023 |
| 3 | LEVOLEUCOVORIN INJECTION | 5 | 0.0016 |
| 4 | PEGASPARGASE | 17 | 0.0014 |
| 5 | APREPITANT | 10 | 0.0013 |
| 6 | LEVOLEUCOVORIN | 5 | 0.0013 |
| 7 | CHLORPROMAZINE HYDROCHLORIDE | 1 | 0.0010 |
| 8 | DALTEPARIN SODIUM | 5 | 0.0005 |
| 9 | PROPAFENONE | 2 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Folate Analog Metabolic Inhibitor [EPC] | 91 |
| 1 | Corticosteroid [EPC] | 27 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 26 |
| 3 | Alkylating Drug [EPC] | 23 |
| 4 | Platinum-based Drug [EPC] | 21 |
| 5 | Proton Pump Inhibitor [EPC] | 18 |
| 6 | Asparagine-specific Enzyme [EPC] | 17 |
| 7 | Serotonin-3 Receptor Antagonist [EPC] | 17 |
| 8 | Azole Antifungal [EPC] | 11 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Carboxypeptidase [EPC] | 2 | 0.0055 |
| 1 | Mucocutaneous Epithelial Cell Growth Factor [EPC] | 1 | 0.0026 |
| 2 | Asparagine-specific Enzyme [EPC] | 17 | 0.0013 |
| 3 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 8 | 0.0009 |
| 4 | Paramagnetic Contrast Agent [EPC] | 1 | 0.0002 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 91 | 0.0002 |
| 6 | Serotonin-3 Receptor Antagonist [EPC] | 17 | 0.0001 |
| 7 | Topoisomerase Inhibitor [EPC] | 8 | 0.0001 |
| 8 | Phenothiazine [EPC] | 3 | 0.0001 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 26 | 0.0001 |